obsessive-compulsive%20disorder
OBSESSIVE-COMPULSIVE DISORDER
Obsessive-compulsive disorder is characterized by the presence of either obsessions or compulsions, but more commonly by both symptoms that can cause marked impairment or distress.
Obsession is a recurrent, persistent, intrusive, unwanted thought, image or urge that cause distressing emotions (eg anxiety and disgust).
Compulsion is a repetitive behavior or mental act that the person feels driven to perform, in order to lessen the distress caused by the obsession.
Anxiety is the central feature of obsessive-compulsive disorder.
Drug Information

Indication: Major depressive episode, panic disorder w/ or w/o agoraphobia, social or generalized anxiety disorder, obsess...

Indication: Depressive illness, symptoms of depressive disorder & obsessive compulsive disorder (OCD).

Indication: Symptomatic treatment of depression including depression accompanied by symptoms of anxiety in patients w/ or ...

Indication: Symptomatic treatment of depression including depression accompanied by symptoms of anxiety. Obsessive compuls...

Indication: Depression & prevention of relapse/recurrence; panic disorder (PD) w/ or w/o agoraphobia; obsessive-compul...

Indication: Major depressive episodes, panic disorder w/ or w/o agoraphobia, social & generalized anxiety disorder, ob...

Indication: Depression, obsessive-compulsive disorder, premenstrual dysphoric disorder (PMDD).

Indication: Symptomatic treatment of depression w/ or w/o anxiety. Obsessive compulsive disorder, pre-menstrual dysphoric ...

Indication: Depression. Bulimia nervosa.

Indication: Major depressive disorder, panic disorder w/ or w/o agoraphobia, premenstrual dysphoric disorder, social anxie...

1  /  3
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 2 days ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, 3 days ago
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
6 days ago
In type 2 diabetes patients taking sulfonylureas, hypoglycaemia duration is longer at night and is inversely correlated with the level of glycated haemoglobin (HbA1c), a new study reports.